GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Return-on-Tangible-Asset

PURE Bioscience (PURE Bioscience) Return-on-Tangible-Asset : -240.29% (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PURE Bioscience's annualized Net Income for the quarter that ended in Jan. 2024 was $-4.01 Mil. PURE Bioscience's average total tangible assets for the quarter that ended in Jan. 2024 was $1.67 Mil. Therefore, PURE Bioscience's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 was -240.29%.

The historical rank and industry rank for PURE Bioscience's Return-on-Tangible-Asset or its related term are showing as below:

PURE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1928.45   Med: -216.45   Max: 0.11
Current: -191.54

During the past 13 years, PURE Bioscience's highest Return-on-Tangible-Asset was 0.11%. The lowest was -1928.45%. And the median was -216.45%.

PURE's Return-on-Tangible-Asset is ranked worse than
98.06% of 1905 companies
in the Consumer Packaged Goods industry
Industry Median: 3.29 vs PURE: -191.54

PURE Bioscience Return-on-Tangible-Asset Historical Data

The historical data trend for PURE Bioscience's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Return-on-Tangible-Asset Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -394.82 0.11 -47.23 -82.91 -125.57

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.14 -160.96 -226.25 -144.29 -240.29

Competitive Comparison of PURE Bioscience's Return-on-Tangible-Asset

For the Household & Personal Products subindustry, PURE Bioscience's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Return-on-Tangible-Asset Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Return-on-Tangible-Asset falls into.



PURE Bioscience Return-on-Tangible-Asset Calculation

PURE Bioscience's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jul. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=-3.961/( (4.484+1.825)/ 2 )
=-3.961/3.1545
=-125.57 %

PURE Bioscience's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-4.008/( (2.25+1.086)/ 2 )
=-4.008/1.668
=-240.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2024) net income data.


PURE Bioscience  (OTCPK:PURE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


PURE Bioscience Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020